|
HU222249B1
(hu)
*
|
1991-03-08 |
2003-05-28 |
Amylin Pharmaceuticals Inc. |
Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
|
|
AU7685894A
(en)
*
|
1993-09-07 |
1995-03-27 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
|
US6143718A
(en)
*
|
1995-06-07 |
2000-11-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of Type II diabetes mellutis with amylin agonists
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US7101853B2
(en)
*
|
1997-05-06 |
2006-09-05 |
Amylin Pharmaceuticals, Inc. |
Method for treating or preventing gastritis using amylin or amylin agonists
|
|
US7910548B2
(en)
*
|
1997-06-06 |
2011-03-22 |
Amylin Pharmaceuticals, Inc. |
Methods for treating obesity
|
|
JP4353544B2
(ja)
*
|
1998-01-09 |
2009-10-28 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
アミリン作動薬ペプチド用製剤
|
|
US6087334A
(en)
*
|
1998-08-21 |
2000-07-11 |
Amylin Pharmaceuticals, Inc. |
Anti-diabetic peptides
|
|
NZ534557A
(en)
*
|
2002-01-08 |
2007-10-26 |
Amylin Pharmaceuticals Inc |
Use of amylin or amylin agonists in the manufacture of a medicament for use in the treatment of dyslipidemia, wherein the medicament reduces post-prandial triglyceride levels
|
|
WO2004004665A2
(en)
*
|
2002-07-09 |
2004-01-15 |
Bristol-Myers Squibb Company |
Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
|
|
AU2004241242A1
(en)
*
|
2003-05-14 |
2004-12-02 |
Emisphere Technologies, Inc. |
Compositions for delivering peptide YY and PYY agonists
|
|
EP1644027B1
(en)
*
|
2003-07-16 |
2014-04-09 |
Evotec International GmbH |
Use of pleiotrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
|
|
EP2233497A3
(en)
*
|
2004-02-11 |
2011-01-12 |
Amylin Pharmaceuticals, Inc. |
Amylin family peptides and methods for making and using them
|
|
JP2007523196A
(ja)
*
|
2004-02-20 |
2007-08-16 |
ライナット ニューロサイエンス コーポレイション |
Ｎｔ−４／５を用いて肥満または糖尿病を処置する方法
|
|
US7399744B2
(en)
*
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
|
EP1888043A4
(en)
*
|
2005-03-11 |
2010-07-28 |
Endo Pharmaceuticals Solutions |
OCTREOTIDE FORMULATIONS WITH CONTROLLED RELEASE
|
|
US7759312B2
(en)
*
|
2005-03-11 |
2010-07-20 |
Endo Pharmaceuticals Solutions Inc. |
Delivery of dry formulations of octreotide
|
|
US7935342B2
(en)
*
|
2006-02-02 |
2011-05-03 |
Rinat Neuroscience Corp. |
Methods for treating obesity by administering a trkB antagonist
|
|
EP1988923A1
(en)
*
|
2006-02-02 |
2008-11-12 |
Rinat Neuroscience Corp. |
Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist
|
|
BRPI0720473A2
(pt)
*
|
2006-12-20 |
2014-01-14 |
Rinat Neuroscience Corp |
Agonistas de trkb para tratamento de distúbios autoimunes
|
|
CA2705708A1
(en)
*
|
2007-11-14 |
2009-05-22 |
Amylin Pharmaceuticals, Inc. |
Methods for treating obesity and obesity related diseases and disorders
|
|
US8071537B2
(en)
*
|
2008-06-25 |
2011-12-06 |
Endo Pharmaceuticals Solutions Inc. |
Implantable device for the sustained release of a polypeptide
|
|
JP5536053B2
(ja)
|
2008-06-25 |
2014-07-02 |
エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド． |
離型剤を有するオクトレオチドインプラント
|
|
EP3228320B1
(de)
|
2008-10-17 |
2019-12-18 |
Sanofi-Aventis Deutschland GmbH |
Kombination von einem insulin und einem glp-1-agonisten
|
|
JP2009149684A
(ja)
*
|
2009-03-11 |
2009-07-09 |
Amylin Pharmaceut Inc |
アミリン作動薬ペプチド用製剤
|
|
EP2762150A1
(en)
*
|
2009-03-12 |
2014-08-06 |
Nordic Bioscience A/S |
Treatment of Diabetes and Metabolic Syndrome
|
|
US20110118180A1
(en)
*
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to metformin
|
|
US20110118178A1
(en)
*
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
|
|
PT2554183T
(pt)
|
2009-11-13 |
2018-07-09 |
Sanofi Aventis Deutschland |
Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
|
|
PE20121316A1
(es)
|
2009-11-13 |
2012-10-05 |
Sanofi Aventis Deutschland |
Composicion farmaceutica que comprende un agonista de glp-1 y metionina
|
|
US20140148384A1
(en)
|
2010-08-30 |
2014-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
CN108079281A
(zh)
|
2011-08-29 |
2018-05-29 |
赛诺菲-安万特德国有限公司 |
用于2型糖尿病患者中的血糖控制的药物组合
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
BR102013017626A2
(pt)
*
|
2013-06-14 |
2015-02-10 |
Univ Rio De Janeiro |
Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
|
|
JP6728141B2
(ja)
*
|
2014-09-04 |
2020-07-22 |
ノヴォ ノルディスク アー／エス |
新規のアミリン及びカルシトニン受容体アゴニスト
|
|
TWI758239B
(zh)
|
2014-12-12 |
2022-03-21 |
德商賽諾菲阿凡提斯德意志有限公司 |
甘精胰島素/利司那肽固定比率配製劑
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|